Key result
Low-dose intracoronary tirofiban linked to severe thrombocytopenia and a ~96% platelet drop in NSTEMI.
Why the study?
Severe thrombocytopenia is a rare but serious complication of tirofiban therapy, including at low intracoronary doses in interventional cardiac procedures.
Case Report (n=1)
No
Even very low doses of intracoronary tirofiban can trigger severe, abrupt, immune-mediated thrombocytopenia, necessitating routine platelet monitoring post-administration.
Necessitates routine platelet monitoring after intracoronary tirofiban; extends immune-mediated thrombocytopenia risk to very low doses.
Tirofiban is a glycoprotein IIb/IIIa inhibitor and is an adjunct in the treatment of patients with acute coronary syndrome. Its main side effects are bleeding and thrombocytopenia. Severe thrombocytopenia is a rare but serious complication of tirofiban therapy, including when administered at low intracoronary doses in interventional cardiac procedures. The pathogenesis is largely immune-mediated and can result in abrupt and profound platelet count declines. Early and frequent platelet monitoring, prompt discontinuation of the drug, and supportive care remain critical to managing this adverse effect. In this case report, we present a case of severe thrombocytopenia that occurred in a 74-year-old male patient with non-ST segment elevation myocardial infarction following administration of a very low dose of tirofiban.
No takes yet. Share an insight, caveat, or question.
Demir et al. (2026) conducted a case report in Non-ST segment elevation myocardial infarction (n=1). Tirofiban was evaluated on Platelet count (x10^9/L). Administration of a low intracoronary dose of tirofiban (10 μg/kg) in a 74-year-old male with NSTEMI caused severe thrombocytopenia, with platelet counts dropping from 200x10^9/L to 9x10^9/L.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: